Find a Researcher
Artak Tovmasyan, PharmD, PhD, is an associate professor in the Department of Translational Neuroscience at Barrow Neurological Institute. He directs the pharmacokinetics core laboratory at the Ivy Brain Tumor Center.
Dr. Tovmasyan’s expertise includes pharmaceutical sciences and drug development, particularly in the field of neuro-oncology. He is a member of the American Association for Cancer Research, the Society for Neuro-Oncology, the Society for Redox Biology and Medicine, and the Society for Porphyrins and Phthalocyanines.
Dr. Tovmasyan earned his PharmD and PhD degrees from the Yerevan State Medical University School of Pharmacy in Armenia, where he also completed a residency in drug development. He completed a postdoctoral fellowship in the Department of Radiation Oncology, Division of Cancer Biology at Duke University Medical Center.
Dr. Tovmasyan’s work in the pharmacokinetics core laboratory involves evaluating drugs used in Phase 0 clinical trials for brain tumor patients. The results obtained in this state-of-the-art laboratory enable doctors to implement the most efficient brain tumor treatment regimens. The lab also provides services in the assessment and design of preclinical pharmacokinetics studies for experimental drugs, collection and processing of specimens, publishing guidance, and assistance with grant applications. Dr. Tovmasyan’s research interests also include medicinal chemistry in the design and development of agents that target the brain, particularly novel radio-modulators for brain tumor therapy.
- Postdoctoral Fellowship, Duke University Medical Center, Department of Radiation Oncology-Cancer Biology, 2009-2014
- PhD, Yerevan State Medical University, School of Pharmacy, Department of Chemistry, Pharmaceutical Sciences, 2008
- Residency, Yerevan State Medical University, School of Pharmacy, Department of Chemistry, Drug Development, 2004-2005
- Internship, Yerevan State Medical University, School of Pharmacy, Department of Chemistry, Drug Development, 2003-2004
- PharmD, Yerevan State Medical University, School of Pharmacy, Department of Chemistry, 2003
- American Association of Cancer Research
- Society for Neuro-Oncology
- Society for Redox Biology and Medicine
- Society of Porphyrins and Phthalocyanines
- Young Investigator Award, 23rd Annual Meeting of Society for Redox Biology and Medicine, 2016
- Young Investigator Award, Duke Cancer Institute, National Cancer Institute Radiation Oncology and Imaging Program Annual Retreat, 2016
- Fellowship Award at Emory University School of Medicine, Society for Redox Biology and Medicine, 2014
- Nominee, National Comprehensive Cancer Network Young Investigator Award, Duke University, 2014
- Fellowship, Friedrich-Alexander University Erlangen-Nürnberg, Department of Bioinorganic Chemistry, 2013
- Fellowship, University of Bourgogne, Institute of Molecular Chemistry, 2008
- Best Oral Presentation, 4th Young Medics’ International Conference, Armenian Medical Association, 2007
- Graduate Research Support Program Award, National Foundation of Science and Advanced Technologies, US Civilian Research and Development Foundation, 2006
- Travel Grant, Yerevan State Medical University, 2006
- Best Oral Presentation, 3rd Young Medics’ International Conference, National Academy of Sciences, 2005
- Travel Grant, 3rd Young Medics’ International Conference, Young Medics’ Association, 2005
A validated LC-MS/MS method for determination of neuro-pharmacokinetic behavior of niraparib in brain tumor patients.
Date: 08/2024
Authors: William Knight, Tigran Margaryan, Nader Sanai, Artak Tovmasyan
Quisinostat is a brain-penetrant radiosensitizer in glioblastoma
Date: 11/2023
Authors: Costanza Lo Cascio, Tigran Margaryan, Ernesto Luna-Melendez, James B. McNamara, Connor I. White, William Knight, Saisrinidhi Ganta, Zorana Opachich, Claudia Cantoni, Wonsuk Yoo, Nader Sanai, Artak Tovmasyan, Shwetal Mehta
Folic Acid Improves Parkin-Null Phenotypes and Transiently Reduces Vulnerable Dopaminergic Neuron Mitochondrial Hydrogen Peroxide Levels and Glutathione Redox Equilibrium
Date: 10/2022
Authors: Katherine L. Houlihan, Lena Mary Houlihan, Petros P. Keoseyan, Amber N. Juba, Tigran Margaryan, Max E. Voss, Alexander M. Babaoghli, Justin M. Norris, Greg J. Adrian, Artak Tovmasyan, Lori M. Buhlman
Simultaneous determination of LY3214996, abemaciclib, and M2 and M20 metabolites in human plasma, cerebrospinal fluid, and brain tumor by LC-MS/MS
Date: 08/2022
Authors: Tigran Margaryan, Mackenna Elliott, Nader Sanai, Artak Tovmasyan
Roles of Phytoestrogen in the Pathophysiology of Intracranial Aneurysm
Date: 01/2021
Authors: Kimihiko Yokosuka, Caleb Rutledge, Yoshinobu Kamio, Atsushi Kuwabara, Hiroki Sato, Redi Rahmani, James Purcell, Satoru Eguchi, Jacob F. Baranoski, Tigran Margaryan, Artak Tovmasyan, Jinglu Ai, J. Ai, Michael T. Lawton, Tomoki Hashimoto
Artak Tovmasyan, PharmD, PhD, is an associate professor in the Department of Translational Neuroscience at Barrow Neurological Institute. He directs the pharmacokinetics core laboratory at the Ivy Brain Tumor Center.
Dr. Tovmasyan’s expertise includes pharmaceutical sciences and drug development, particularly in the field of neuro-oncology. He is a member of the American Association for Cancer Research, the Society for Neuro-Oncology, the Society for Redox Biology and Medicine, and the Society for Porphyrins and Phthalocyanines.
Dr. Tovmasyan earned his PharmD and PhD degrees from the Yerevan State Medical University School of Pharmacy in Armenia, where he also completed a residency in drug development. He completed a postdoctoral fellowship in the Department of Radiation Oncology, Division of Cancer Biology at Duke University Medical Center.
Dr. Tovmasyan’s work in the pharmacokinetics core laboratory involves evaluating drugs used in Phase 0 clinical trials for brain tumor patients. The results obtained in this state-of-the-art laboratory enable doctors to implement the most efficient brain tumor treatment regimens. The lab also provides services in the assessment and design of preclinical pharmacokinetics studies for experimental drugs, collection and processing of specimens, publishing guidance, and assistance with grant applications. Dr. Tovmasyan’s research interests also include medicinal chemistry in the design and development of agents that target the brain, particularly novel radio-modulators for brain tumor therapy.
- Postdoctoral Fellowship, Duke University Medical Center, Department of Radiation Oncology-Cancer Biology, 2009-2014
- PhD, Yerevan State Medical University, School of Pharmacy, Department of Chemistry, Pharmaceutical Sciences, 2008
- Residency, Yerevan State Medical University, School of Pharmacy, Department of Chemistry, Drug Development, 2004-2005
- Internship, Yerevan State Medical University, School of Pharmacy, Department of Chemistry, Drug Development, 2003-2004
- PharmD, Yerevan State Medical University, School of Pharmacy, Department of Chemistry, 2003
- American Association of Cancer Research
- Society for Neuro-Oncology
- Society for Redox Biology and Medicine
- Society of Porphyrins and Phthalocyanines
- Young Investigator Award, 23rd Annual Meeting of Society for Redox Biology and Medicine, 2016
- Young Investigator Award, Duke Cancer Institute, National Cancer Institute Radiation Oncology and Imaging Program Annual Retreat, 2016
- Fellowship Award at Emory University School of Medicine, Society for Redox Biology and Medicine, 2014
- Nominee, National Comprehensive Cancer Network Young Investigator Award, Duke University, 2014
- Fellowship, Friedrich-Alexander University Erlangen-Nürnberg, Department of Bioinorganic Chemistry, 2013
- Fellowship, University of Bourgogne, Institute of Molecular Chemistry, 2008
- Best Oral Presentation, 4th Young Medics’ International Conference, Armenian Medical Association, 2007
- Graduate Research Support Program Award, National Foundation of Science and Advanced Technologies, US Civilian Research and Development Foundation, 2006
- Travel Grant, Yerevan State Medical University, 2006
- Best Oral Presentation, 3rd Young Medics’ International Conference, National Academy of Sciences, 2005
- Travel Grant, 3rd Young Medics’ International Conference, Young Medics’ Association, 2005
A validated LC-MS/MS method for determination of neuro-pharmacokinetic behavior of niraparib in brain tumor patients.
Date: 08/2024
Authors: William Knight, Tigran Margaryan, Nader Sanai, Artak Tovmasyan
Quisinostat is a brain-penetrant radiosensitizer in glioblastoma
Date: 11/2023
Authors: Costanza Lo Cascio, Tigran Margaryan, Ernesto Luna-Melendez, James B. McNamara, Connor I. White, William Knight, Saisrinidhi Ganta, Zorana Opachich, Claudia Cantoni, Wonsuk Yoo, Nader Sanai, Artak Tovmasyan, Shwetal Mehta
Folic Acid Improves Parkin-Null Phenotypes and Transiently Reduces Vulnerable Dopaminergic Neuron Mitochondrial Hydrogen Peroxide Levels and Glutathione Redox Equilibrium
Date: 10/2022
Authors: Katherine L. Houlihan, Lena Mary Houlihan, Petros P. Keoseyan, Amber N. Juba, Tigran Margaryan, Max E. Voss, Alexander M. Babaoghli, Justin M. Norris, Greg J. Adrian, Artak Tovmasyan, Lori M. Buhlman
Simultaneous determination of LY3214996, abemaciclib, and M2 and M20 metabolites in human plasma, cerebrospinal fluid, and brain tumor by LC-MS/MS
Date: 08/2022
Authors: Tigran Margaryan, Mackenna Elliott, Nader Sanai, Artak Tovmasyan
Roles of Phytoestrogen in the Pathophysiology of Intracranial Aneurysm
Date: 01/2021
Authors: Kimihiko Yokosuka, Caleb Rutledge, Yoshinobu Kamio, Atsushi Kuwabara, Hiroki Sato, Redi Rahmani, James Purcell, Satoru Eguchi, Jacob F. Baranoski, Tigran Margaryan, Artak Tovmasyan, Jinglu Ai, J. Ai, Michael T. Lawton, Tomoki Hashimoto